ChemoMetec A/S (CHEMM) - Net Assets
Based on the latest financial reports, ChemoMetec A/S (CHEMM) has net assets worth Dkr652.59 Million DKK (≈ $102.10 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Dkr783.37 Million ≈ $122.56 Million USD) and total liabilities (Dkr130.78 Million ≈ $20.46 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ChemoMetec A/S (CHEMM) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Dkr652.59 Million |
| % of Total Assets | 83.31% |
| Annual Growth Rate | N/A |
| 5-Year Change | 154.12% |
| 10-Year Change | 1084.46% |
| Growth Volatility | 41.19 |
ChemoMetec A/S - Net Assets Trend (2004–2025)
This chart illustrates how ChemoMetec A/S's net assets have evolved over time, based on quarterly financial data. Also explore ChemoMetec A/S (CHEMM) total assets for the complete picture of this company's asset base.
Annual Net Assets for ChemoMetec A/S (2004–2025)
The table below shows the annual net assets of ChemoMetec A/S from 2004 to 2025. For live valuation and market cap data, see ChemoMetec A/S (CHEMM) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | Dkr673.36 Million ≈ $105.35 Million |
+19.11% |
| 2024-06-30 | Dkr565.32 Million ≈ $88.45 Million |
+6.05% |
| 2023-06-30 | Dkr533.04 Million ≈ $83.40 Million |
+49.23% |
| 2022-06-30 | Dkr357.20 Million ≈ $55.89 Million |
+34.81% |
| 2021-06-30 | Dkr264.98 Million ≈ $41.46 Million |
+30.69% |
| 2020-06-30 | Dkr202.75 Million ≈ $31.72 Million |
+16.97% |
| 2019-06-30 | Dkr173.34 Million ≈ $27.12 Million |
+137.42% |
| 2018-06-30 | Dkr73.01 Million ≈ $11.42 Million |
+13.41% |
| 2017-06-30 | Dkr64.38 Million ≈ $10.07 Million |
+13.24% |
| 2016-06-30 | Dkr56.85 Million ≈ $8.89 Million |
+22.65% |
| 2015-06-30 | Dkr46.35 Million ≈ $7.25 Million |
+4.09% |
| 2014-06-30 | Dkr44.53 Million ≈ $6.97 Million |
+3.00% |
| 2013-06-30 | Dkr43.23 Million ≈ $6.76 Million |
+0.87% |
| 2012-06-30 | Dkr42.86 Million ≈ $6.71 Million |
-18.69% |
| 2011-06-30 | Dkr52.71 Million ≈ $8.25 Million |
+0.16% |
| 2010-06-30 | Dkr52.62 Million ≈ $8.23 Million |
-6.55% |
| 2009-06-30 | Dkr56.31 Million ≈ $8.81 Million |
+8.89% |
| 2008-06-30 | Dkr51.71 Million ≈ $8.09 Million |
+31.47% |
| 2007-06-30 | Dkr39.34 Million ≈ $6.15 Million |
+138.47% |
| 2006-06-30 | Dkr16.50 Million ≈ $2.58 Million |
+245.47% |
| 2005-06-30 | Dkr-11.34 Million ≈ $-1.77 Million |
-12.66% |
| 2004-06-30 | Dkr-10.06 Million ≈ $-1.57 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ChemoMetec A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 67603300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Dkr664.70 Million | 98.71% |
| Common Stock | Dkr17.40 Million | 2.58% |
| Other Comprehensive Income | Dkr-8.74 Million | -1.30% |
| Total Equity | Dkr673.36 Million | 100.00% |
ChemoMetec A/S Competitors by Market Cap
The table below lists competitors of ChemoMetec A/S ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chutian Dragon Co Ltd
SHE:003040
|
$925.81 Million |
|
Jiangsu Hanvo Safety Product Co. Ltd.
SHE:300952
|
$926.35 Million |
|
Cello World Limited
NSE:CELLO
|
$926.37 Million |
|
HangZhou Radical Energy Saving Technology Co Ltd
SHE:300652
|
$926.58 Million |
|
Sungho Electronics Corp
KQ:043260
|
$925.14 Million |
|
GCI Liberty, Inc.
NASDAQ:GLIBK
|
$925.01 Million |
|
Ulker Biskuvi Sanayi AS
IS:ULKER
|
$924.68 Million |
|
TOA PAINT (THAILAND)
BK:TOA-R
|
$924.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ChemoMetec A/S's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 565,316,000 to 673,355,000, a change of 108,039,000 (19.1%).
- Net income of 186,405,000 contributed positively to equity growth.
- Dividend payments of 69,600,000 reduced retained earnings.
- Other comprehensive income decreased equity by 8,765,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Dkr186.41 Million | +27.68% |
| Dividends Paid | Dkr69.60 Million | -10.34% |
| Other Comprehensive Income | Dkr-8.77 Million | -1.3% |
| Other Changes | Dkr-1.00 | -0.0% |
| Total Change | Dkr- | 19.11% |
Book Value vs Market Value Analysis
This analysis compares ChemoMetec A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.79x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-06-30 | Dkr-792.02 | Dkr340.00 | x |
| 2005-06-30 | Dkr-892.27 | Dkr340.00 | x |
| 2006-06-30 | Dkr1025.81 | Dkr340.00 | x |
| 2007-06-30 | Dkr2.26 | Dkr340.00 | x |
| 2008-06-30 | Dkr3.13 | Dkr340.00 | x |
| 2009-06-30 | Dkr3.18 | Dkr340.00 | x |
| 2010-06-30 | Dkr3.03 | Dkr340.00 | x |
| 2011-06-30 | Dkr3.03 | Dkr340.00 | x |
| 2012-06-30 | Dkr2.47 | Dkr340.00 | x |
| 2013-06-30 | Dkr2.49 | Dkr340.00 | x |
| 2014-06-30 | Dkr2.56 | Dkr340.00 | x |
| 2015-06-30 | Dkr2.96 | Dkr340.00 | x |
| 2016-06-30 | Dkr3.63 | Dkr340.00 | x |
| 2017-06-30 | Dkr4.11 | Dkr340.00 | x |
| 2018-06-30 | Dkr4.71 | Dkr340.00 | x |
| 2019-06-30 | Dkr11.14 | Dkr340.00 | x |
| 2020-06-30 | Dkr12.03 | Dkr340.00 | x |
| 2021-06-30 | Dkr15.23 | Dkr340.00 | x |
| 2022-06-30 | Dkr20.53 | Dkr340.00 | x |
| 2023-06-30 | Dkr30.63 | Dkr340.00 | x |
| 2024-06-30 | Dkr32.48 | Dkr340.00 | x |
| 2025-06-30 | Dkr38.69 | Dkr340.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ChemoMetec A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 27.68%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 37.61%
- • Asset Turnover: 0.60x
- • Equity Multiplier: 1.23x
- Recent ROE (27.68%) is above the historical average (14.68%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 0.00% | -115.79% | 1.67x | 0.00x | Dkr-9.01 Million |
| 2005 | 0.00% | -20.57% | 1.45x | 0.00x | Dkr-1.22 Million |
| 2006 | 24.82% | 28.03% | 0.46x | 1.94x | Dkr2.44 Million |
| 2007 | 2.14% | 3.78% | 0.43x | 1.31x | Dkr-3.09 Million |
| 2008 | 25.58% | 29.52% | 0.80x | 1.08x | Dkr8.06 Million |
| 2009 | 8.17% | 14.35% | 0.49x | 1.16x | Dkr-1.03 Million |
| 2010 | -7.01% | -11.31% | 0.52x | 1.19x | Dkr-8.95 Million |
| 2011 | 0.20% | 0.29% | 0.61x | 1.15x | Dkr-5.16 Million |
| 2012 | -23.02% | -25.17% | 0.79x | 1.16x | Dkr-14.15 Million |
| 2013 | 0.80% | 0.84% | 0.81x | 1.18x | Dkr-3.98 Million |
| 2014 | 2.58% | 2.54% | 0.88x | 1.15x | Dkr-3.30 Million |
| 2015 | 17.15% | 12.98% | 0.96x | 1.37x | Dkr3.31 Million |
| 2016 | 18.44% | 12.30% | 0.94x | 1.59x | Dkr4.80 Million |
| 2017 | 11.63% | 8.29% | 0.93x | 1.52x | Dkr1.05 Million |
| 2018 | 24.95% | 16.16% | 0.99x | 1.56x | Dkr10.91 Million |
| 2019 | 24.14% | 23.84% | 0.74x | 1.37x | Dkr24.51 Million |
| 2020 | 29.18% | 27.63% | 0.81x | 1.30x | Dkr38.89 Million |
| 2021 | 33.34% | 31.43% | 0.82x | 1.30x | Dkr61.86 Million |
| 2022 | 44.64% | 37.23% | 0.85x | 1.40x | Dkr123.75 Million |
| 2023 | 33.52% | 40.20% | 0.68x | 1.23x | Dkr125.36 Million |
| 2024 | 24.11% | 33.41% | 0.60x | 1.20x | Dkr79.75 Million |
| 2025 | 27.68% | 37.61% | 0.60x | 1.23x | Dkr119.07 Million |
Industry Comparison
This section compares ChemoMetec A/S's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,196,604,454
- Average return on equity (ROE) among peers: 19.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ChemoMetec A/S (CHEMM) | Dkr652.59 Million | 0.00% | 0.20x | $925.73 Million |
| Ambu A/S (AMBU-B) | $294.12 Million | 8.84% | 0.89x | $2.44 Billion |
| Demant A/S (DEMANT) | $756.47 Million | 104.51% | 2.82x | $7.91 Billion |
| GN Store Nord (GN) | $4.85 Billion | 29.99% | 2.44x | $2.13 Billion |
| Scandinavian Medical Solutions AS (SMSMED) | $74.45 Million | 16.42% | 1.20x | $12.52 Million |
| ViroGates A/S (VIRO) | $8.98 Million | -60.13% | 0.34x | $15.97 Million |
About ChemoMetec A/S
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, an… Read more